S&P 500 may face selling pressure as systematic funds reach full exposure
SOUTH SAN FRANCISCO, Calif. - Senti Biosciences, Inc. (NASDAQ: SNTI), a clinical-stage biotechnology company valued at $130 million, announced positive preliminary data from a Phase 1 clinical trial of SENTI-202, a potential new treatment for relapsed or refractory hematologic malignancies, including acute myeloid leukemia (AML). The company’s stock has shown remarkable momentum, gaining over 123% in the past six months. The results were presented at the American Association for Cancer Research (AACR) Annual Meeting 2025.According to InvestingPro, the company’s stock currently trades near overbought levels, with analysts setting a $12 price target.
The study reported no dose-limiting toxicities and identified a preliminary recommended Phase 2 dose (RP2D). Out of seven evaluable patients, five achieved an overall response rate (ORR), with three complete remissions (CR), one CR with partial hematologic recovery (CRh), and one achieving a morphologic leukemia-free state. Additionally, four patients who achieved complete composite remission (cCR) were found to be measurable residual disease (MRD) negative.
The safety profile of SENTI-202 was consistent with other investigational natural killer (NK) cell therapies, with adverse events primarily related to lymphodepleting chemotherapy rather than the investigational therapy itself. No grade 5 adverse events were recorded.
The Phase 1 study continues to enroll patients to confirm the preliminary RP2D, followed by disease-specific expansion cohorts. The trial is partially funded by a grant from the California Institute for Regenerative Medicine.
Senti Biosciences also shared preliminary financial results for the first quarter of 2025, with cash and cash equivalents of approximately $33.8 million. The company maintains a healthy current ratio of 4.49, indicating strong short-term liquidity, though InvestingPro data shows rapid cash burn remains a concern. Research and development expenses increased slightly to $9.3 million, while general and administrative expenses decreased to $7.1 million. The net loss for the quarter was $14.1 million.
In addition to the SENTI-202 data, Senti Biosciences is evaluating the next steps for its SENTI-301A/SN301A program after observing certain dose-limiting toxicities in an Investigator Sponsored Trial.
The company will host a webcast today at 8:30 AM ET to discuss the new Phase 1 SENTI-202 data. This information is based on a press release statement.Investors should note that while Senti Biosciences maintains more cash than debt on its balance sheet, the company’s financial health score from InvestingPro remains "FAIR," with analysts not expecting profitability this year. InvestingPro subscribers have access to 10 additional key insights about SNTI’s financial position and market performance.
In other recent news, Senti Biosciences has made several notable announcements. The company recently appointed James B. Trager, Ph.D., to its Scientific Advisory Board, bringing over 25 years of expertise in cellular therapy development for cancer. This appointment is expected to bolster Senti Bio’s oncology programs, including its lead candidate, SENTI-202, which is currently in Phase I clinical trials targeting hematologic cancers. Additionally, Senti Bio has joined Webull’s Corporate Connect Service to enhance communication with shareholders and increase market visibility. The company has also expanded its Board of Directors with the addition of Feng Hsiung, who brings extensive experience in business and finance. During a recent Special Meeting, Senti Bio’s stockholders approved amendments to the company’s 2022 Equity Incentive Plan, adding flexibility for stock conversion and incentivizing employees and directors. These developments reflect Senti Bio’s ongoing efforts to advance its cell and gene therapy programs and strengthen its corporate governance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.